An interventional study of Exercogs® and Control in Dementia, sponsored by Eduarda Oliosi, MS. Recruiting at 1 site in Portugal. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Eduarda Oliosi, MS · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Dementia with a site in Portugal — 9 open to participants now, 9 under way, 1 of them phase 3. Dementia · Portugal.
Among the 34 studies in Dementia with a site in Portugal, this one is the 10th largest by planned enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2026, is one of 24 with no phase, and was the 33rd registered.
2,377 studies on the registry are indexed under Dementia; 572 are open to participants now.
Browse Dementia studies →9 of the 34 studies in Dementia with a site in Portugal are open now. Recruiting first, the newest first:
University Rovira i Virgili · Sites in Portugal
Ages 18+
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Portugal, Australia, Austria and 14 more countries
Ages 18+
Universidade do Porto · Sites in Portugal
Ages 65+ · Healthy volunteers
MapLight Therapeutics · Sites in Portugal, United States, Argentina and 12 more countries
Ages 55–90
Bristol-Myers Squibb · Sites in Portugal, United States, Argentina and 14 more countries
Ages 60–85
A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →
Of the 382 Dementia studies recruiting now, 242 (63%) set no upper age limit and 25 (7%) stop at 75 or younger; 15 take children under 18; 163 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 90 across 1,761 interventional studies indexed under Dementia.
Median enrollment 104 across the 30 interventional studies, 176 across the 4 observational. Of the 19 that completed or were terminated, 3 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 34 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Eduarda Oliosi, MS as lead sponsor.
Eduarda Oliosi, MS has 1 study filed under Dementia — fewer than ten, so there is no comparison to draw.
1 of the studies in Dementia with a site in Portugal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07577440University Rovira i VirgiliEffectiveness of the Self-Control Module of a Positive Mental Health Promotion Programme for Adult Informal Caregivers of People With Dementia: Protocol for a Randomised Controlled Trial | 2027-05-02 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies in Dementia with a site in Portugal, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background: Multidomain, technology-based interventions represent a promising approach to dementia prevention by simultaneously targeting cognitive, physical, and social domains. Exercogs® is a novel exergaming platform combining augmented reality (AR) and gamification, designed to deliver tailored, interactive, and multidomain training. This study aims to evaluate the feasibility, safety, and efficacy of Exercogs® when implemented as part of a community-based dementia prevention program for older adults at risk.
Methods: This is a randomized, controlled, assessor-blind, parallel-group, multicenter trial. One hundred and fifty community-dwelling adults, aged 55 years or older, with at least one modifiable dementia risk factor, will be randomly assigned (1:1) to either the Exercogs® intervention group or the active control group. Both groups will complete 60-minute supervised sessions three times per week for 24 weeks. The Exercogs® program integrates cognitive (e.g., attention, memory, and executive function), physical (e.g., balance, gait, and coordination), and social (e.g., cooperative and competitive) activities within a gamified AR environment. The difficulty levels are adaptable to the participants' individual abilities. The control group will perform equivalent non-AR exercises, i.e., the control group will receive a conventional multidomain group program with the same frequency and duration. Outcomes will be assessed at baseline, 12 weeks, 24 weeks (end of intervention), and 4 and 8 weeks post-intervention. The co-primary endpoints are changes in global cognition (Montreal Cognitive Assessment-Portuguese Version, MoCA-PT), physical performance (Short Physical Performance Battery, SPPB), and social participation (World Health Organization Disability Assessment Schedule, WHODAS 2.0). Secondary outcomes include usability (System Usability Scale, SUS-PT; Exercogs® group only), health-related quality of life (EQ-5D-5L), safety (adverse events, including falls, dizziness, and fatigue), and changes in modifiable risk load. Exploratory outcomes include digital engagement and in-game performance metrics automatically captured by the Exercogs® platform. Feasibility will be assessed by session adherence (≥70% completion).
Results: The protocol has been approved by the Casa de Saúde da Idanha Ethics Committee (Nº6/2025) and funded by the Instituto da Segurança Social, I.P. Preliminary findings are expected in 2026 and will provide comprehensive evidence on the efficacy, feasibility, usability, and safety of Exercogs® as a multidomain digital intervention.
Conclusions: This trial will evaluate a scalable, technology-driven, multidomain intervention for older adults at risk of dementia, integrating cognitive, physical, and social training within an AR environment and gamification. If effective, Exercogs® could serve as a model for community-based dementia prevention and inform public health strategies for healthy aging.
Background:
Age-related cognitive decline is a major public health challenge, increasingly burdening healthcare and social protection systems. Large-scale multidomain trials, including FINGER, MAPT, and preDIVA, have shown that multicomponent interventions are more effective in reducing dementia risk than single-domain approaches. The latest Lancet Commission identified 14 modifiable risk factors accounting for up to 45% of potentially preventable dementia cases, highlighting the importance of coordinated prevention strategies. Recent research also emphasizes the role of social and structural determinants, such as socioeconomic factors, HIV infection, and gender, in expanding the global applicability of prevention models. Notably, evidence suggests that multidomain interventions may benefit individuals irrespective of genetic risk.
Given dementia's multifactorial etiology, multidomain interventions are particularly well-suited to address interrelated risk factors, including physical inactivity, social isolation, and cognitive underuse, by simultaneously targeting biological, behavioral, and psychosocial determinants of cognitive aging. Advances in digital health technologies have expanded the reach and feasibility of such programs. Digital tools, including computerized cognitive training and exergaming, have shown promise in improving cognition, physical function, and social engagement among older adults. Extended reality technologies, including virtual and augmented reality (AR), further enhance these interventions by providing immersive, interactive, and adaptive environments that improve motivation, adherence, and learning.
Integrating gamification into AR-based exergames can transform solitary exercises into socially engaging activities, supporting mood, social interaction, and psychological well-being. Systematic reviews confirm benefits across cognitive, physical, and emotional domains, including memory, attention, executive function, mobility, balance, strength, and overall functional capacity. Social (multiplayer) exergames, in particular, offer engaging experiences that support aerobic exercise and enhance social well-being, including reduced loneliness, increased social connection, and more positive attitudes toward others. Feasibility studies further indicate high acceptability, safety, and applicability in home and community settings, with minimal spatial requirements. Nevertheless, while AR-based interventions appear effective, small sample sizes and high heterogeneity limit the generalizability of current findings, emphasizing the need for larger, more standardized trials.
Despite promising preliminary evidence, rigorous trials evaluating AR-based gamified interventions in community-dwelling older adults remain scarce, particularly those assessing multidomain outcomes spanning cognitive, physical, and social dimensions. There is also a need to systematically examine engagement, usability, and real-world applicability to ensure that such interventions can be feasibly scaled and adapted to individual abilities. Delivering a multidomain program through a gamified AR platform could provide an engaging, adaptive, and scalable approach to enhancing cognitive, physical, and social functioning in older adults at risk of cognitive decline. Accordingly, this trial aims to evaluate the efficacy and safety of a gamified AR-based multidomain intervention (Exercogs®) on global cognition, physical performance, and social participation (MoCA, SPPB, WHODAS 2.0).
Objectives and Hypotheses:
This study aims to assess the efficacy and feasibility of Exercogs®, a digital multidomain intervention combining AR and gamification to integrate cognitive, physical, and social training, for the prevention of cognitive decline in community-dwelling older adults.
H1: Participants receiving Exercogs® will show greater improvements in cognitive performance, physical function, and social participation compared with the control group after 24 weeks.
H2: Intervention effects will be maintained at follow-up (4-8 weeks post-intervention).
H3: The number of baseline modifiable risk factors (risk burden) will moderate the magnitude of intervention effects.
Methods in brief:
We will conduct a randomized, controlled, rater-blind, parallel-group, multicenter clinical trial. Participants will undergo assessments at baseline, 12 weeks, 24 weeks (end of intervention), and follow-up (4 and 8 weeks post-intervention).
Exercogs® Group (A): Participants will undertake structured 60-minute sessions three times per week for 24 weeks. Each session integrates physical training (balance, gait, and coordination exercises), cognitive stimulation (attention, memory, and executive functions), and social engagement activities (cooperative and competitive tasks). All activities are delivered within a gamified AR environment designed to enhance engagement and adapt difficulty to individual abilities. The intervention follows a predefined, progressive protocol tailored to each participant's performance.
Control Group (B): Participants will engage in a conventional multidomain program matched for frequency and duration (60 minutes, three times per week, 24 weeks), comprising standard physical, cognitive, and social exercises without AR or gamification.
After providing written informed consent, eligible community-dwelling adults aged 55 years or older with at least one modifiable risk factor for dementia will undergo a comprehensive baseline assessment. Demographic, clinical, and medication information will be collected through structured interviews. Outcome assessments will be conducted by assessors blinded to group allocation and independent of the intervention team, minimizing the risk of assessment bias. The same assessors will perform all evaluations throughout the study to ensure consistency. Session adherence, as well as any missed sessions, adverse events, or protocol deviations, will be recorded in real time using standardized reporting forms. Adherence for the Exercogs® group will be monitored via automated platform logs, whereas attendance for both groups will also be tracked using therapist-completed diaries.
Expected impact:
This study will provide robust evidence on the efficacy, usability, and scalability of Exercogs® as a digital, multidomain preventive intervention for adults aged 55 years and older who are at risk for dementia. The findings may inform the integration of digital health solutions into community- and national-level dementia prevention programs, supporting the implementation of evidence-based strategies for healthy aging.
If successful, this study will be the first randomized controlled trial to evaluate a gamified, AR-based multidomain intervention for the prevention of cognitive decline in community-dwelling adults, addressing cognitive, physical, and social domains simultaneously, with strong potential for adoption within Portugal's public health system.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will undertake structured 60-minute sessions three times per week for 24 weeks. Each session integrates physical training (balance, gait, and coordination exercises), cognitive stimulation (attention, memory, and executive functions), and social engagement activities (cooperative and competitive tasks). All activities are delivered within a gamified AR environment designed to enhance engagement and adapt difficulty to individual abilities. The intervention follows a predefined, progressive protocol tailored to each participant's performance.
Other: Exercogs®
Participants will engage in a conventional multidomain program matched for frequency and duration (60 minutes, three times per week, 24 weeks), comprising standard physical, cognitive, and social exercises without AR or gamification.
Other: Control
The Exercogs® interevention integrates cognitive (e.g., attention, memory, and executive function), physical (e.g., balance, gait, and coordination), and social (e.g., cooperative and competitive) activities within a gamified AR environment. The difficulty levels are adaptable to the participants' individual abilities. The control group will perform equivalent non-AR exercises, i.e., the control group will receive a conventional multidomain group program with the same frequency and duration.
Participants in the control intervention, will engage in a conventional multidomain program matched for frequency and duration (60 minutes, three times per week, 24 weeks), comprising standard physical, cognitive, and social exercises without AR or gamification.
Global cognitive function (MoCA total score, points)
Global cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA). Total scores range from 0 to 30 points, with higher scores indicating better cognitive performance.
Time frame: From baseline to week 24, with assessments at baseline, week 12, week 24 (end of intervention), and at 4 and 8 weeks post-intervention.
Physical performance (SPPB total score, points)
Physical performance will be measured using the Short Physical Performance Battery (SPPB). Total scores range from 0 to 12 points, with higher scores indicating better lower extremity function.
Time frame: From baseline to week 24, with assessments at baseline, week 12, week 24 (end of intervention), and at 4 and 8 weeks post-intervention.
Social participation (WHODAS 2.0 total score, points)
Functioning and social participation will be assessed using the 12-item World Health Organization Disability Assessment Schedule (WHODAS 2.0). Total scores range from 0 to 100 points, with higher scores indicating greater disability.
Time frame: From baseline to week 24, with assessments at baseline, week 12, week 24 (end of intervention), and at 4 and 8 weeks post-intervention.
Usability (SUS total score, points)
Usability will be assessed using the System Usability Scale (SUS). Total scores range from 0 to 100, with higher scores indicating better usability.
Time frame: At week 24 (end of intervention).
Health-related quality of life (EQ-5D-5L utility index)
Health-related quality of life will be assessed using the EQ-5D-5L. Responses will be converted into a single utility index using the Portuguese value set. Higher scores indicate better health status.
Time frame: At week 24 (end of intervention).
Number of participants with adverse events (count)
Number of participants experiencing at least one adverse event during the intervention period, including falls, dizziness, and fatigue.
Time frame: From baseline through week 24, with safety assessments recorded at weeks 1, 12, and 24.
Number of modifiable dementia risk factors (count)
Total number of modifiable risk factors per participant based on clinical assessment and self-reported medical history (physical inactivity, hypertension, obesity, smoking, depression, low social engagement, hearing loss, vision loss, diabetes, excessive alcohol use, dyslipidemia).
Time frame: From baseline through week 24, with assessments at baseline, week 12, and week 24.
Intervention adherence (percentage of completed Exercogs sessions)
Intervention adherence will be assessed as the percentage of prescribed Exercogs training sessions completed during the 24-week intervention, based on automatically recorded platform data.
Time frame: From baseline through week 24 (end of intervention).
Plan to share: No — IPD will not be shared due to participant confidentiality and ethical considerations regarding sensitive health data.
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Aug 2026, 7 months after the start.
Of 862 non-industry interventional studies with no phase under Dementia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 7 months is below that.
Counting every sponsor, half of 908 studies reached it within 25 months; a quarter within 11 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.